Improving postoperative radiotherapy following radical prostatectomy

References

• Roach M 3rd, Ceron Lizarraga TL, Lazar AA. Radical prostatectomy versus radiation and androgen deprivation therapy for clinically localized prostate cancer: how good is the evidence? Int J Radiat Oncol Biol Phys. 2015;93:1064–1070.
   PubMed Web of Science ®Google Scholar
• Hamdy FC, Donovan JL, Lane JA, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375:1415–1424.
   PubMed Web of Science ®Google Scholar
• Novara G, Ficarra V, Mocellin S, et al. Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol. 2012;62:382–404.
   PubMed Web of Science ®Google Scholar
• Boorjian SA, Eastham JA, Graefen M, et al. A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Eur Urol. 2012;61:664–675.
   PubMed Web of Science ®Google Scholar
• Wilson T, Torrey R. Open versus robotic-assisted radical prostatectomy: which is better? Curr Opin Urol. 2011;21:200–205.
   PubMed Web of Science ®Google Scholar
• Freedland SJ, Humphreys EB, Mangold LA, et al. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol. 2007;25:1765–1771.
   PubMed Web of Science ®Google Scholar
• Cher ML, Bianco FJ Jr., Lam JS, et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol. 1998;160:1387–1391.
   PubMed Web of Science ®Google Scholar
• Thomas CT, Bradshaw PT, Pollock BH, et al. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol. 2003;21:1715–1721.
   PubMed Web of Science ®Google Scholar
• Leventis AK, Shariat SF, Slawin KM. Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. Radiology. 2001;219:432–439.
   PubMed Web of Science ®Google Scholar
• Koppie TM, Grossfeld GD, Nudell DM, et al. Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy? J Urol. 2001;166:111–115.
   PubMed Web of Science ®Google Scholar
• Swanson GP, Lerner SP. Positive margins after radical prostatectomy: implications for failure and role of adjuvant treatment. Urol Oncol. 2013;31:531–541.
   PubMed Web of Science ®Google Scholar
• Han M, Partin AW, Chan DY, et al. An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. J Urol. 2004;171:23–26.
   PubMed Web of Science ®Google Scholar
• Tewari A, Sooriakumaran P, Bloch DA, et al. Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy. Eur Urol. 2012;62:1–15.
   PubMed Web of Science ®Google Scholar
• Sooriakumaran P, Dev HS, Skarecky D, et al. The importance of surgical margins in prostate cancer. J Surg Oncol. 2016;113:310–315.
   PubMed Web of Science ®Google Scholar
• Sakr WA, Wheeler TM, Blute M, et al. Staging and reporting of prostate cancer–sampling of the radical prostatectomy specimen. Cancer. 1996;78:366–368.
   PubMed Web of Science ®Google Scholar
• van der Kwast TH, Collette L, van Poppel H, et al. Impact of pathology review of stage and margin status of radical prostatectomy specimens (EORTC trial 22911). Virchows Arch. 2006;449:428–434.
   PubMed Web of Science ®Google Scholar
• Fontenot PA, Mansour AM. Reporting positive surgical margins after radical prostatectomy: time for standardization. BJU Int. 2013;111:E290–E299.
   PubMed Web of Science ®Google Scholar
• Saether T, Sorlien LT, Viset T, et al. Are positive surgical margins in radical prostatectomy specimens an independent prognostic marker? Scand J Urol Nephrol. 2008;42:514–521.
   PubMed Web of Science ®Google Scholar
• Jayachandran J, Banez LL, Levy DE, et al. Risk stratification for biochemical recurrence in men with positive surgical margins or extracapsular disease after radical prostatectomy: results from the SEARCH database. J Urol. 2008;179:1791–6; discussion 1796.
   PubMed Web of Science ®Google Scholar
• Porpiglia F, Fiori C, Manfredi M, et al. Surgical margin status of specimen and oncological outcomes after laparoscopic radical prostatectomy: experience after 400 procedures. World J Urol. 2012;30:245–250.
   PubMed Web of Science ®Google Scholar
• Simon MA, Kim S, Soloway MS. Prostate specific antigen recurrence rates are low after radical retropubic prostatectomy and positive margins. J Urol. 2006;175:140–145.
   PubMed Web of Science ®Google Scholar
• Kordan Y, Salem S, Chang SS, et al. Impact of positive apical surgical margins on likelihood of biochemical recurrence after radical prostatectomy. J Urol. 2009;182:2695–2701.
   PubMed Web of Science ®Google Scholar
• Stephenson AJ, Wood DP, Kattan MW, et al. Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. J Urol. 2009;182:1357–1363.
   PubMed Web of Science ®Google Scholar
• Savdie R, Horvath LG, Benito RP, et al. High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy. BJU Int. 2012;109:1794–1800.
   PubMed Web of Science ®Google Scholar
• Shikanov S, Song J, Royce C, et al. Length of positive surgical margin after radical prostatectomy as a predictor of biochemical recurrence. J Urol. 2009;182:139–144.
   PubMed Web of Science ®Google Scholar
• Godoy G, Tareen BU, Lepor H. Site of positive surgical margins influences biochemical recurrence after radical prostatectomy. BJU Int. 2009;104:1610–1614.
   PubMed Web of Science ®Google Scholar
• Pfitzenmaier J, Pahernik S, Tremmel T, et al. Positive surgical margins after radical prostatectomy: do they have an impact on biochemical or clinical progression? BJU Int. 2008;102:1413–1418.
   PubMed Web of Science ®Google Scholar
• Somford DM, van Oort IM, Cosyns JP, et al. Prognostic relevance of number and bilaterality of positive surgical margins after radical prostatectomy. World J Urol. 2012;30:105–110.
   PubMed Web of Science ®Google Scholar
• May M, Brookman-May S, Weissbach L, et al. Solitary and small (</=3 mm) apical positive surgical margins are related to biochemical recurrence after radical prostatectomy. Int J Urol. 2011;18:282–289.
   PubMed Web of Science ®Google Scholar
• Boorjian SA, Tollefson MK, Rangel LJ, et al. Clinicopathological predictors of systemic progression and prostate cancer mortality in patients with a positive surgical margin at radical prostatectomy. Prostate Cancer Prostatic Dis. 2012;15:56–62.
   PubMed Web of Science ®Google Scholar
• Ploussard G, Agamy MA, Alenda O, et al. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naive patients. BJU Int. 2011;107:1748–1754.
   PubMed Web of Science ®Google Scholar
• Hsu M, Chang SL, Ferrari M, et al. Length of site-specific positive surgical margins as a risk factor for biochemical recurrence following radical prostatectomy. Int J Urol. 2011;18:272–279.
   PubMed Web of Science ®Google Scholar
• Cao D, Humphrey PA, Gao F, et al. Ability of linear length of positive margin in radical prostatectomy specimens to predict biochemical recurrence. Urology. 2011;77:1409–1414.
   PubMed Web of Science ®Google Scholar
• Lake AM, He C, Wood DP Jr. Focal positive surgical margins decrease disease-free survival after radical prostatectomy even in organ-confined disease. Urology. 2010;76:1212–1216.
   PubMed Web of Science ®Google Scholar
• Brimo F, Partin AW, Epstein JI. Tumor grade at margins of resection in radical prostatectomy specimens is an independent predictor of prognosis. Urology. 2010;76:1206–1209.
   PubMed Web of Science ®Google Scholar
• Chuang AY, Nielsen ME, Hernandez DJ, et al. The significance of positive surgical margin in areas of capsular incision in otherwise organ confined disease at radical prostatectomy. J Urol. 2007;178:1306–1310.
   PubMed Web of Science ®Google Scholar
• Pettus JA, Weight CJ, Thompson CJ, et al. Biochemical failure in men following radical retropubic prostatectomy: impact of surgical margin status and location. J Urol. 2004;172:129–132.
   PubMed Web of Science ®Google Scholar
• Tozawa K, Yasui T, Umemoto Y, et al. Pitfalls of robot-assisted radical prostatectomy: a comparison of positive surgical margins between robotic and laparoscopic surgery. Int J Urol. 2014;21:976–979.
   PubMed Web of Science ®Google Scholar
• Fesseha T, Sakr W, Grignon D, et al. Prognostic implications of a positive apical margin in radical prostatectomy specimens. J Urol. 1997;158:2176–2179.
   PubMed Web of Science ®Google Scholar
• Ohori M, Abbas F, Wheeler TM, et al. Pathological features and prognostic significance of prostate cancer in the apical section determined by whole mount histology. J Urol. 1999;161:500–504.
   PubMed Web of Science ®Google Scholar
• Poulos CK, Koch MO, Eble JN, et al. Bladder neck invasion is an independent predictor of prostate-specific antigen recurrence. Cancer. 2004;101:1563–1568.
   PubMed Web of Science ®Google Scholar
• Aydin H, Tsuzuki T, Hernandez D, et al. Positive proximal (bladder neck) margin at radical prostatectomy confers greater risk of biochemical progression. Urology. 2004;64:551–555.
   PubMed Web of Science ®Google Scholar
• Sofer M, Hamilton-Nelson KL, Civantos F, et al. Positive surgical margins after radical retropubic prostatectomy: the influence of site and number on progression. J Urol. 2002;167:2453–2456.
   PubMed Web of Science ®Google Scholar
• Yossepowitch O, Sircar K, Scardino PT, et al. Bladder neck involvement in pathological stage pT4 radical prostatectomy specimens is not an independent prognostic factor. J Urol. 2002;168:2011–2015.
   PubMed Web of Science ®Google Scholar
• Obek C, Sadek S, Lai S, et al. Positive surgical margins with radical retropubic prostatectomy: anatomic site-specific pathologic analysis and impact on prognosis. Urology. 1999;54:682–688.
   PubMed Web of Science ®Google Scholar
• Dash A, Sanda MG, Yu M, et al. Prostate cancer involving the bladder neck: recurrence-free survival and implications for AJCC staging modification. American Joint Committee on Cancer. Urology. 2002;60:276–280.
   PubMed Web of Science ®Google Scholar
• Bastide C, Savage C, Cronin A, et al. Location and number of positive surgical margins as prognostic factors of biochemical recurrence after salvage radiation therapy after radical prostatectomy. BJU Int. 2010;106:1454–1457.
   PubMed Web of Science ®Google Scholar
• Vickers A, Bianco F, Cronin A, et al. The learning curve for surgical margins after open radical prostatectomy: implications for margin status as an oncological end point. J Urol. 2010;183:1360–1365.
   PubMed Web of Science ®Google Scholar
• Secin FP, Savage C, Abbou C, et al. The learning curve for laparoscopic radical prostatectomy: an international multicenter study. J Urol. 2010;184:2291–2296.
   PubMed Web of Science ®Google Scholar
• Sooriakumaran P, John M, Wiklund P, et al. Learning curve for robotic assisted laparoscopic prostatectomy: a multi-institutional study of 3794 patients. Minerva Urol Nefrol. 2011;63:191–198.
   PubMed Web of Science ®Google Scholar
• Tefilli MV, Gheiler EL, Tiguert R, et al. Prognostic indicators in patients with seminal vesicle involvement following radical prostatectomy for clinically localized prostate cancer. J Urol. 1998;160:802–806.
   PubMed Web of Science ®Google Scholar
• Swanson GP, Riggs M, Hermans M. Pathologic findings at radical prostatectomy: risk factors for failure and death. Urol Oncol. 2007;25:110–114.
   PubMed Web of Science ®Google Scholar
• Hong YM, Sutherland DE, Linder B, et al. “Learning curve” may not be enough: assessing the oncological experience curve for robotic radical prostatectomy. J Endourol. 2010;24:473–477.
   PubMed Web of Science ®Google Scholar
• Budaus L, Isbarn H, Eichelberg C, et al. Biochemical recurrence after radical prostatectomy: multiplicative interaction between surgical margin status and pathological stage. J Urol. 2010;184:1341–1346.
   PubMed Web of Science ®Google Scholar
• Wiegel T, Bartkowiak D, Bottke D, et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol. 2014;66:243–250.
   PubMed Web of Science ®Google Scholar
• Swanson GP, Yu C, Kattan MW, et al. Validation of postoperative nomograms in prostate cancer patients with long-term follow-up. Urology. 2011;78:105–109.
   PubMed Web of Science ®Google Scholar
• Brajtbord JS, Leapman MS, Cooperberg MR. The CAPRA score at 10 years: contemporary perspectives and analysis of supporting studies. Eur Urol. 2016;71:705-709.
   PubMed Web of Science ®Google Scholar
• Stephenson AJ, Scardino PT, Eastham JA, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2005;23:7005–7012.
   PubMed Web of Science ®Google Scholar
• Suardi N, Porter CR, Reuther AM, et al. A nomogram predicting long-term biochemical recurrence after radical prostatectomy. Cancer. 2008;112:1254–1263.
   PubMed Web of Science ®Google Scholar
• Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181:956–962.
   PubMed Web of Science ®Google Scholar
• Swanson GP, Hussey MA, Tangen CM, et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol. 2007;25:2225–2229.
   PubMed Web of Science ®Google Scholar
• Bolla M, Van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012;380:2018–2027.
   PubMed Web of Science ®Google Scholar
• Daly T, Hickey BE, Lehman M, et al. Adjuvant radiotherapy following radical prostatectomy for prostate cancer. Cochrane Database Syst Rev. 2011;12.
   Web of Science ®Google Scholar
• Kalbasi A, Swisher-McClure S, Mitra N, et al. Low rates of adjuvant radiation in patients with nonmetastatic prostate cancer with high-risk pathologic features. Cancer. 2014;120:3089–3096.
   PubMed Web of Science ®Google Scholar
• Chen C, Lin T, Zhou Y, et al. Adjuvant and salvage radiotherapy after prostatectomy: a systematic review and meta-analysis. PLoS One. 2014;9:e104918.
   PubMed Web of Science ®Google Scholar
• Fossati N, Karnes RJ, Boorjian SA, et al. Long-term impact of adjuvant versus early salvage radiation therapy in pT3N0 prostate cancer patients treated with radical prostatectomy: results from a multi-institutional series. Eur Urol. 2016;15:e544.
   Google Scholar
• Briganti A, Wiegel T, Joniau S, et al. Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. Eur Urol. 2012;62:472–487.
   PubMed Web of Science ®Google Scholar
• Ost P, De Troyer B, Fonteyne V, et al. A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2011;80:1316–1322.
   PubMed Web of Science ®Google Scholar
• Abugharib A, Jackson WC, Tumati V, et al. Very early salvage radiotherapy improves distant metastasis-free survival. J Urol. 2016;197:662-668.
   PubMed Web of Science ®Google Scholar
• Fossati N, Karnes RJ, Cozzarini C, et al. Assessing the optimal timing for early salvage radiation therapy in patients with prostate-specific antigen rise after radical prostatectomy. Eur Urol. 2016;69:728–733.
   PubMed Web of Science ®Google Scholar
• Seisen T, Trinh QD, Abdollah F. Could lead-time bias explain the apparent benefits of early salvage radiotherapy? Nat Rev Urol. 2017;14:193–194.
   PubMed Web of Science ®Google Scholar
• Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008;299:2760–2769.
   PubMed Web of Science ®Google Scholar
• Stephenson AJ, Scardino PT, Bianco FJ Jr., et al. Salvage therapy for locally recurrent prostate cancer after external beam radiotherapy. Curr Treat Options Oncol. 2004;5:357–365.
   PubMedGoogle Scholar
• Mauermann J, Fradet V, Lacombe L, et al. The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment-naive pT2-4 N0 radical prostatectomy patients. Eur Urol. 2013;64:19–25.
   PubMed Web of Science ®Google Scholar
• Abdollah F, Suardi N, Cozzarini C, et al. Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol. 2013;63:998–1008.
   PubMed Web of Science ®Google Scholar
• Gandaglia G, Karakiewicz PI, Briganti A, et al. Early radiotherapy after radical prostatectomy improves cancer-specific survival only in patients with highly aggressive prostate cancer: validation of recently released criteria. Int J Urol. 2015;22:89–95.
   PubMed Web of Science ®Google Scholar
• Jia ZW, Chang K, Dai B, et al. Factors influencing biochemical recurrence in patients who have received salvage radiotherapy after radical prostatectomy: a systematic review and meta-analysis. Asian J Androl. 2017;19:493-499.
   PubMed Web of Science ®Google Scholar
• Parker C, Sydes MR, Catton C, et al. Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy. BJU Int. 2007;99:1376–1379.
   PubMed Web of Science ®Google Scholar
• Pearse M, Fraser-Browne C, Davis ID, et al. A phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy – Adjuvant Versus Early Salvage (RAVES) trial. BJU Int. 2014;113(Suppl 2):7–12.
   PubMed Web of Science ®Google Scholar
• Shipley WU, Seiferheld W, Lukka HR, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med. 2017;376:417–428.
   PubMed Web of Science ®Google Scholar
• Carrie C, Hasbini A, De Laroche G, et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 2016;17:747–756.
   PubMed Web of Science ®Google Scholar
• Zhao SG, Chang SL, Spratt DE, et al. Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. Lancet Oncol. 2016;17:1612–1620.
   PubMed Web of Science ®Google Scholar
• Den RB, Yousefi K, Trabulsi EJ, et al. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J Clin Oncol. 2015;33:944–951.
   PubMed Web of Science ®Google Scholar
• Tilki D, Mandel P, Schlomm T, et al. External validation of the CAPRA-S score to predict biochemical recurrence, metastasis and mortality after radical prostatectomy in a European cohort. J Urol. 2015;193:1970–1975.
   PubMed Web of Science ®Google Scholar
• Cozzarini C, Fiorino C, Da Pozzo LF, et al. Clinical factors predicting late severe urinary toxicity after postoperative radiotherapy for prostate carcinoma: a single-institute analysis of 742 patients. Int J Radiat Oncol Biol Phys. 2012;82:191–199.
   PubMed Web of Science ®Google Scholar
• King CR. The dose-response of salvage radiotherapy following radical prostatectomy: a systematic review and meta-analysis. Radiother Oncol. 2016;121:199–203.
   PubMed Web of Science ®Google Scholar
• Riou O, Laliberte B, Azria D, et al. Implementing intensity modulated radiotherapy to the prostate bed: dosimetric study and early clinical results. Med Dosim. 2013;38:117–121.
   PubMed Web of Science ®Google Scholar
• Ost P, Fonteyne V, Villeirs G, et al. Adjuvant high-dose intensity-modulated radiotherapy after radical prostatectomy for prostate cancer: clinical results in 104 patients. Eur Urol. 2009;56:669–675.
   PubMed Web of Science ®Google Scholar
• D’Angelillo RM, Sciuto R, Ramella S, et al. (1, 8)F-choline positron emission tomography/computed tomography-driven high-dose salvage radiation therapy in patients with biochemical progression after radical prostatectomy: feasibility study in 60 patients. Int J Radiat Oncol Biol Phys. 2014;90:296–302.
   PubMed Web of Science ®Google Scholar
• Ghadjar P, Gwerder N, Manser P, et al. High-dose (80 Gy) intensity-modulated radiation therapy with daily image-guidance as primary treatment for localized prostate cancer. Strahlenther Onkol. 2010;186:687–692.
   PubMed Web of Science ®Google Scholar
• Cozzarini C, Fiorino C, Deantoni C, et al. Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients. Eur Urol. 2014;66:1024–1030.
   PubMed Web of Science ®Google Scholar
• Buchser D, Gomez-Iturriaga A, Melcon JI, et al. Salvage high-dose-rate brachytherapy for histologically confirmed macroscopic local relapsed prostate cancer after radical prostatectomy. J Contemp Brachytherapy. 2016;8:477–483.
   PubMed Web of Science ®Google Scholar
• Strom TJ, Wilder RB, Fernandez DC, et al. High-dose-rate brachytherapy with or without intensity modulated radiation therapy as salvage treatment for an isolated, gross local recurrence of prostate cancer post-prostatectomy. Brachytherapy. 2014;13:123–127.
   PubMed Web of Science ®Google Scholar
• Kumar AM, Smith KL, Reddy CA, et al. Safety and efficacy of salvage low-dose-rate brachytherapy for prostate bed recurrences following radical prostatectomy. J Contemp Brachytherapy. 2015;7:241–246.
   PubMed Web of Science ®Google Scholar
• Hosogoe S, Soma O, Matsumoto T, et al. Salvage brachytherapy for castration-resistant and external beam radiotherapy-resistant local recurrence 17 years after radical prostatectomy. Case Rep Urol. 2015;2015:839738.
   PubMedGoogle Scholar
• Gaztanaga M, Crook JM. Permanent seed brachytherapy for locally recurrent prostate cancer after radical prostatectomy: a case report and review of the literature. Brachytherapy. 2013;12:338–342.
   PubMed Web of Science ®Google Scholar
• Gomez-Veiga F, Marino A, Alvarez L, et al. Brachytherapy for the treatment of recurrent prostate cancer after radiotherapy or radical prostatectomy. BJU Int. 2012;109(Suppl 1):17–21.
   PubMed Web of Science ®Google Scholar
• Traudt K, Ciezki J, Klein EA. Low-dose-rate brachytherapy as salvage treatment of local prostate cancer recurrence after radical prostatectomy. Urology. 2011;77:1416–1419.
   PubMed Web of Science ®Google Scholar
• Losa A, Nava LD, Di Muzio N, et al. Salvage brachytherapy for local recurrence after radical prostatectomy and subsequent external beam radiotherapy. Urology. 2003;62:1068–1072.
   PubMed Web of Science ®Google Scholar
• Nobes JP, Khaksar SJ, Hawkins MA, et al. Novel prostate brachytherapy technique: improved dosimetric and clinical outcome. Radiother Oncol. 2008;88:121–126.
   PubMed Web of Science ®Google Scholar
• Pinkawa M, Fischedick K, Piroth MD, et al. Health-related quality of life after permanent interstitial brachytherapy for prostate cancer: correlation with postimplant CT scan parameters. Strahlenther Onkol. 2006;182:660–665.
   PubMed Web of Science ®Google Scholar
• Poortmans P, Bossi A, Vandeputte K, et al. Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother Oncol. 2007;84:121–127.
   PubMed Web of Science ®Google Scholar
• Michalski JM, Lawton C, El Naqa I, et al. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010;76:361–368.
   PubMed Web of Science ®Google Scholar
• Sidhom MA, Kneebone AB, Lehman M, et al. Post-prostatectomy radiation therapy: consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group. Radiother Oncol. 2008;88:10–19.
   PubMed Web of Science ®Google Scholar
• Wiltshire KL, Brock KK, Haider MA, et al. Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2007;69:1090–1099.
   PubMed Web of Science ®Google Scholar
• Ost P, De Meerleer G, Vercauteren T, et al. Delineation of the postprostatectomy prostate bed using computed tomography: interobserver variability following the EORTC delineation guidelines. Int J Radiat Oncol Biol Phys. 2011;81:e143–9.
   PubMed Web of Science ®Google Scholar
• Park JS, Park W, Pyo HR, et al. Suggestion for the prostatic fossa clinical target volume in adjuvant or salvage radiotherapy after a radical prostatectomy. Radiother Oncol. 2014;110:240–244.
   PubMed Web of Science ®Google Scholar
• Manji M, Crook J, Schmid M, et al. Target volume definition for post prostatectomy radiotherapy: do the consensus guidelines correctly define the inferior border of the CTV? Rep Pract Oncol Radiother. 2016;21:525–531.
   PubMedGoogle Scholar
• Spiotto MT, Hancock SL, King CR. Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int J Radiat Oncol Biol Phys. 2007;69:54–61.
   PubMed Web of Science ®Google Scholar
• Song C, Kang HC, Kim JS, et al. Elective pelvic versus prostate bed-only salvage radiotherapy following radical prostatectomy: a propensity score-matched analysis. Strahlenther Onkol. 2015;191:801–809.
   PubMed Web of Science ®Google Scholar
• Deville C, Vapiwala N, Hwang WT, et al. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy. Int J Radiat Oncol Biol Phys. 2012;82:1389–1396.
   PubMed Web of Science ®Google Scholar
• Alongi F, Fiorino C, Cozzarini C, et al. IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiother Oncol. 2009;93:207–212.
   PubMed Web of Science ®Google Scholar
• Verma V, Chen L, Michalski JM, et al. Evaluation of 3 T pelvic MRI imaging in prostate cancer patients receiving post-prostatectomy IMRT. World J Urol. 2015;33:69–75.
   PubMed Web of Science ®Google Scholar
• Muller BG, Kaushal A, Sankineni S, et al. Multiparametric magnetic resonance imaging-transrectal ultrasound fusion-assisted biopsy for the diagnosis of local recurrence after radical prostatectomy. Urol Oncol. 2015;33:425.e1-6.
   Web of Science ®Google Scholar
• Yu T, Meng N, Chi D, et al. Diagnostic value of dynamic contrast-enhanced magnetic resonance imaging in detecting residual or recurrent prostate cancer after radical prostatectomy: a pooled analysis of 12 individual studies. Cell Biochem Biophys. 2015;72:687–694.
   PubMed Web of Science ®Google Scholar
• Dirix P, van Walle L, Deckers F, et al. Proposal for magnetic resonance imaging-guided salvage radiotherapy for prostate cancer. Acta Oncol. 2016;56:27-32.
   PubMed Web of Science ®Google Scholar
• Lawton CA, Michalski J, El-Naqa I, et al. RTOG GU radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2009;74:383–387.
   PubMed Web of Science ®Google Scholar
• Meijer HJ, van Lin EN, Debats OA, et al. High occurrence of aberrant lymph node spread on magnetic resonance lymphography in prostate cancer patients with a biochemical recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2012;82:1405–1410.
   PubMed Web of Science ®Google Scholar
• Evangelista L, Zattoni F, Guttilla A, et al. Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. Clin Nucl Med. 2013;38:305–314.
   PubMed Web of Science ®Google Scholar
• Fanti S, Minozzi S, Castellucci P, et al. PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data. Eur J Nucl Med Mol Imaging. 2016;43:55–69.
   PubMed Web of Science ®Google Scholar
• Vees H, Buchegger F, Albrecht S, et al. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int. 2007;99:1415–1420.
   PubMed Web of Science ®Google Scholar
• Schillaci O, Calabria F, Tavolozza M, et al. Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2012;39:589–596.
   PubMed Web of Science ®Google Scholar
• Bluemel C, Linke F, Herrmann K, et al. Impact of 68Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy. EJNMMI Res. 2016;6:78.
   PubMed Web of Science ®Google Scholar
• Freitag MT, Radtke JP, Afshar-Oromieh A, et al. Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. Eur J Nucl Med Mol Imaging. 2017;44:776-787.
   PubMed Web of Science ®Google Scholar
• Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid (6, 8)Ga-PSMA Ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668–674.
   PubMed Web of Science ®Google Scholar
• Schwenck J, Rempp H, Reischl G, et al. Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. Eur J Nucl Med Mol Imaging. 2017;44:92–101.
   PubMed Web of Science ®Google Scholar
• Cooperberg MR, Carroll PR. Trends in management for patients with localized prostate cancer, 1990-2013. JAMA. 2015;314:80–82.
   PubMed Web of Science ®Google Scholar
• Ost P, Jereczek-Fossa BA, van As N, et al. Pattern of progression after stereotactic body radiotherapy for oligometastatic prostate cancer nodal recurrences. Clin Oncol (R Coll Radiol). 2016;28:e115–e120.
   PubMed Web of Science ®Google Scholar
• Park SY, Kim CK, Park BK, et al. Early changes in apparent diffusion coefficient from diffusion-weighted MR imaging during radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2012;83:749–755.
   PubMed Web of Science ®Google Scholar